PRNewsWire
23 Oct 2025, 14:00 UTC · 45w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Exelixis disclosed high incidence of severe side effects in its STELLAR-303 phase 3 trial for zanzalintinib, alongside immature data for a primary endpoint subgroup. — Safety concerns and incomplete efficacy data in a pivotal phase 3 trial significantly jeopardize the drug's path to approval and future revenue.
-0.80Exelixis has decided not to proceed to the phase 3 portion of the STELLAR-305 study for advanced squamous cell carcinoma of the head and neck. — Abandoning a clinical trial represents a loss of R&D investment and a reduction in the company's long-term pipeline potential.
-0.60Pomerantz LLP is investigating claims of securities fraud and unlawful business practices against Exelixis and its officers. — The initiation of a securities fraud investigation creates legal overhang and potential liability for the company.
-0.40Continue reading
6 related stories
Top 3 movers · tap to explore
Net product revenues for cabozantinib were approximately 2% below consensus estimates for the second quarter of 2025. — While a miss, the small margin suggests a minor deviation from expectations rather than a fundamental collapse in demand.
-0.20Which stocks this story touches
The company is being investigated for potential securities fraud following missed revenue estimates, trial cancellations, and safety concerns leading to significant stock price drops.
The company is under investigation by a law firm on behalf of its investors.
The company is facing a class action lawsuit causing losses for investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
1d ago
